Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
SAN DIEGO--(BUSINESS WIRE)--May 14, 2024-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22in San Diego, California.
圣地亚哥--(美国商业资讯)--2024年5月14日-- Gossamer Bio, Inc. 纳斯达克股票代码：GOSS）是一家临床阶段的生物制药公司，专注于开发和商业化用于治疗肺动脉高压（PH-ILD）和与间质性肺病（PH-ILD）相关的肺动脉高压（PH-ILD）的肺动脉高压，将在5月17日至22日举行的美国胸科学会2024年国际会议上公布最新的seralutinib TORREY开放标签扩展数据在加利福尼亚州圣地亚哥。
Details for the oral presentation related to seralutinib, an inhaled, PDGFR, CSF1R and c-KIT inhibitor, designed for the treatment of pulmonary hypertension, are as follows:
与塞拉鲁替尼（一种吸入式、PDGFR、CSF1R 和 C-kit 抑制剂，专为治疗肺动脉高压而设计）相关的口头陈述详情如下：
Session: A14: Building Lego(Land): Lessons Learned From Large Scale Clinical Trials In PAH
Session Date & Time: Sunday, May 19th, 9:15 a.m. - 11:15 a.m. PT
Talk Title: Interim Results from the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
Location: San Diego Convention Center, Room 29A-D (Upper Level)
Presenting Author: Olivier Sitbon, MD, PhD
会话： A14：建造乐高（乐园）：从PAH的大规模临床试验中吸取的经验教训
会话日期和时间： 5 月 19 日星期日第四，太平洋时间上午 9:15-上午 11:15
讲座标题： Seralutinib治疗肺动脉高压（PAH）的1B期和2期TORREY开放标签延期研究的中期结果
地点： 圣地亚哥会议中心，29A-D 室（上层）
主讲作者： 奥利维尔·西特邦，医学博士
Gossamer also will present additional data on seralutinib via poster. Details for those posters are as follows:
Gossamer还将通过海报展示有关塞拉替尼的更多数据。这些海报的详细信息如下：
Poster Board Number: 424
Poster Session: D105 Balboa Park Explorers: Translational Science and Epidemiology in PH
Session Date & Time: Wednesday, May 22nd, 11:00 a.m. – 1:00 p.m. PT
Poster Title: TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation, and Fibrosis Improve with Treatment
Location: San Diego Convention Center, Room 25A-C (Upper Level)
海报板编号： 424
海报会议： D105 巴尔博亚公园探险家：PH 中的转化科学和流行病学
会话日期和时间： 5月22日星期三和，太平洋时间上午 11:00 — 下午 1:00
海报标题： TORREY Seralutinib 治疗肺动脉高压 (PAH) 的 2 期研究：治疗后增殖、炎症和纤维化的循环生物标志物得到改善
地点： 圣地亚哥会议中心，25A-C 会议室（上层）
Poster Board Number: 318
Poster Session: D109 Now We Got Bad Blood: RSF/PC Joint Session on Pulmonary Vascular Disease
Session Date & Time: Wednesday, May 22nd, 11:00 a.m. – 1:00 p.m. PT
Poster Title: Cardiac Effort Is Less Variable Than Six-minute Walk Distance, Correlates with Hemodynamics and Is Consistent with REVEAL 2.0 Risk Score in a Sub-study of the TORREY Phase 2 PAH Trial
Location: San Diego Convention Center, Room 28C-E (Upper Level)
海报板编号： 318
海报会议： D109 现在我们得了坏血：RSF/PC 肺血管病联席会议
会话日期和时间： 5月22日星期三和，太平洋时间上午 11:00 — 下午 1:00
海报标题： 在TORREY 2期PAH试验的子研究中，心脏运动量的变化小于六分钟的步行距离，与血液动力学相关，与REVEAL 2.0风险评分一致
地点： 圣地亚哥会议中心，28C-E 室（上层）
About Gossamer Bio
关于 Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.
Gossamer Bio是一家临床阶段的生物制药公司，专注于用于治疗肺动脉高压的血清替尼的开发和商业化。其目标是成为肺动脉高压的行业领导者，并改善肺动脉高压患者的生活。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514616477/en/
For Investors and Media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com
对于投资者和媒体：
布莱恩·吉罗多，首席运营官兼首席财务官
Gossamer Bio 投资者关系
ir@gossamerbio.com
Source: Gossamer Bio, Inc.
来源：Gossamer Bio, Inc.